Benefit of magnesium-25 carrying porphyrin-fullerene nanoparticles in experimental diabetic neuropathy

International Journal of Nanomedicine

Volumn 5, Issue 1, 2010, Pages 517-523

  Hosseini, Asieh ^a   Sharifzadeh, Mohammad ^a   Rezayat, Seyed Mahdi ^a   Hassanzadeh, Gholamreza ^a   Hassani, Shokoufeh ^a   Baeeri, Maryam ^a   Shetab Bushehri, Vahid ^b   Kuznetsov, Dmitry A ^c   Abdollahi, Mohammad ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

25Mg magnetic isotope effect; Adenosine triphosphate; Diabetes; Nanotechnology; Neuropathy; Oxidative stress; Porphyrin fullerene nanoparticles

Indexed keywords

2,3 DIPHOSPHOGLYCERIC ACID; ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; ANTIOXIDANT; BIOLOGICAL MARKER; GLUCOSE; MAGNESIUM CHLORIDE; MAGNESIUM PORPHYLLEREN MC16 MG 25; NANOPARTICLE; STREPTOZOCIN; THIOL GROUP; UNCLASSIFIED DRUG; FULLERENE C60; FULLERENE DERIVATIVE; ISOTOPE; MAGNESIUM; PORPHYRIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DIABETIC NEUROPATHY; DISEASE MODEL; DRUG EFFECT; GLUCOSE BLOOD LEVEL; LD 50; LIPID PEROXIDATION; MALE; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; RAT; SPINAL GANGLION; TREATMENT DURATION; ANIMAL; BLOOD; CHEMISTRY; DRUG DELIVERY SYSTEM; HUMAN; METABOLISM; NANOMEDICINE; PATHOLOGY; WISTAR RAT;

ANIMALIA; RATTUS;

2,3-DIPHOSPHOGLYCERATE; ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; ANIMALS; DIABETIC NEUROPATHIES; DRUG DELIVERY SYSTEMS; FULLERENES; GANGLIA, SPINAL; HUMANS; ISOTOPES; MAGNESIUM; MALE; NANOMEDICINE; NANOPARTICLES; OXIDATIVE STRESS; PORPHYRINS; RATS; RATS, WISTAR;

EID: 77958522543     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047-1053.
2. Raymond Azman A. Management of diabetic neuropathy. Malaysian Journal of Medical Science. 2003;10(2):27-30.
3. Figueroa-Romero C, Sadidi M, Feldman EL. Mechanisms of disease: the oxidative stress theory of diabetic neuropathy. Rev Endocr Metab Disord. 2008;9(4):301-314.
4. Fernyhough P, Huang TJ, Verkhratsky A. Mechanism of mitochondrial dysfunction in diabetic sensory neuropathy. J Peripher Nerv Syst. 2003; 8(4):227-235.
5. Douglas W, Zochodne MD. Diabetic Neuropathies. Neuromuscul Disord. 2000;2:23-29.
6. Rahimi R, Nikfar S, Larijani B, Abdollahi M. A review on the role of antioxidants in the management of diabetes and its complications. Biomed Pharmacother. 2005;59(7):365-373.
7. Rezayat SM, Boushehri SV, Salmanian B, et al. The porphyrin-fullerene nanoparticles to promote the ATP overproduction in myocardium: 25Mg2?-magnetic isotope effect. Eur J Med Chem. 2009;44(4): 1554-1569.
8. Amirshahi N, Alyautdin RN, Sarkar S, et al. Porphyrin-fullerene nanoparticles for treatment of hypoxic cardiopathies. Nanotechnol Russ. 2008;3(10):611-621.
9. Bosi S, Da Ros T, Spalluto G, Prato M. Fullerene derivatives: an attractive tool for biological applications. Eur J Med Chem. 2003;38(11-12): 913-923.
10. Wu AS, Kiaei M, Aguirre N, et al. Iron porphyrin treatment extends survival in a transgenic animal model of amyotrophic lateral sclerosis. J Neurochem. 2003;85(1):142-150.
11. Süzer T, Coskun E, Islekel H, Tahta K. Neuroprotective effect of magnesium on lipid peroxidation and axonal function after experimental spinal cord injury. Spinal Cord. 1999;37(7):480-484.
12. Zhou H, Ma Y, Zhou Y, Liu Z, Wang K, Chen G. Effects of magnesium sulfate on neuron apoptosis and expression of caspase-3, bax and bcl-2 after cerebral ischemia-reperfusion injury. Chin Med J (Engl). 2003;116(10):1532-1534.
13. Srinivasan S, Stevens M, Wiley JW. Diabetic peripheral neuropathy: evidence for apoptosis and associated mitochondrial dysfunction. Diabetes. 2000;49(11):1932-1938.
14. Castilho EM, Glass ML, Manço JC. The effects of 2,3-diphosphoglycerate, adenosine triphosphate, and glycosylated hemoglobin on the hemoglobin- oxygen affinity of diabetic patients. Braz J Med Biol Res. 2003;36(6):731-737.
15. Benzi IF, Strain S. Ferric reducing antioxidant power assay: direct measure of total antioxidant activity of biological fluids and modified version for simultaneous measurement of total antioxidant power and ascorbic acid concentration. Methods Enzymol. 1999;292:15-27.
16. Hu ML, Dillared CJ. Plasma SH and GSH measurement. Methods Enzymol. 1994;233:385-387.
17. Ranjbar A, Solhi H, Jalali Mashayekhi F, Susanabdi A, Rezaie A, Abdollahi M. Oxidative stress in acute human poisoning with organophosphorus insecticides; a case control study. Environ Toxicol Pharmacol. 2005;20(1):88-91.
18. Chen Y, Xing D, Wang W, Ding Y, Du L. Development of an ion-pair HPLC method for investigation of energy charge changes in cerebral ischemia of mice and hypoxia of Neuro-2a cell line. Biomed Chromatogr. 2007;21(6):628-634.
19. Lewis R Goldfrank, Neal Flomenbaum, Mary Ann Howland, Robert S Hoffman, Neal A Lewin, Lewis S Goldfranks. Toxicologic Emergencies. 8th ed. Nelson-Medical; 2006:238.
20. Nakamura J, Koh N, Sakakibara F, et al. Polyol pathway, 2,3- diphosphoglycerate in erythrocytes and diabetic neuropathy in rats. Eur J Pharmacol. 1995;294(1):207-214.
21. Bunn HF, Ransil BJ, Chao A. The interaction between erythrocyte organic phosphates, magnesium ion, and hemoglobin. J Biol Chem. 1971;246(17):5273-5279.
22. Garby L, Gerber G, De Verdier CH. Binding of 2,3-diphosphoglycerate and adenosine triphosphate to human haemoglobin A. Eur J Biochem. 1969;10(1):110-115.
23. Shahbazi P, Maleknia N. General Biochemistry for Students of Medical Sciences. Tehran, Iran: Tehran University Press; 2001;(2):194.
24. Buchachenko AL, Kouznetsov DA, Orlova MA, Markarian AA. Magnetic isotope effect of magnesium in phosphoglycerate kinase phosphorylation. Proc Natl Acad Sci U S A. 2005;102(31):10793-10796.
25. Schmeichel AM, Schmelzer JD, Low PA. Oxidative injury and apoptosis of dorsal root ganglion neurons in chronic experimental diabetic neuropathy. Diabetes. 2003;52(1):165-171.
26. Russell JW, Golovoy D, Vincent AM, et al. High glucose-induced oxidative stress and mitochondrial dysfunction in neurons. FASEB J. 2002;16(13):1738-1748.
27. Wang IC, Tai LA, Lee DD, et al. C(60) and water-soluble fullerene derivatives as antioxidants against radical-initiated lipid peroxidation. J Med Chem. 1999;42(22):4614-4620.
28. Motohashi N, Takahashi A, Mifune M, Saito Y. Inhibitory effects of water-soluble cationic manganese porphyrins on peroxynitrite-induced SOS response in Salmonella typhimurium TA4107/pSK1002. Mutat Res. 2004;554(1-2):165-174.
29. Pessoto FS, Inada NM, Nepomuceno Mde F, et al. Biological effects of anionic meso-tetrakis (para-sulfonatophenyl) porphyrins modulated by the metal center. Studies in rat liver mitochondria. Chem Biol Interact. 2009;181(3):400-408.
30. Astaneie F, Afshari M, Mojtahedi A, et al. Total antioxidant capacity and levels of epidermal growth factor and nitric oxide in blood and saliva of insulin-dependent diabetic patients. Arch Med Res. 2005; 36(4):376-381.
31. Afshari M, Larijani B, Rezaie A, et al. Ineffectiveness of allopurinol in reduction of oxidative stress in diabetic patients; a randomized, double-blind placebo-controlled clinical trial. Biomed Pharmacother. 2004;58(10):546-550.
32. Markovic Z, Trajkovic V. Biomedical potential of the reactive oxygen species generation and quenching by fullerenes (C60). Biomaterials. 2008;29(26):3561-3573.
33. Lin CY, Tsai PS, Hung YC, Huang CJ. L-type calcium channels are involved in mediating the anti-inflammatory effects of magnesium sulphate. Br J Anaesth. 2010;104(1):44-51.
34. Pajoumand A, Shadnia S, Rezaie A, Abdi M, Abdollahi M. Benefits of magnesium sulfate in the management of acute human poisoning by organophosphorus insecticides. Hum Exp Toxicol. 2004;23(12): 565-569.
35. De Leeuw I, Engelen W, De Block C, Van Gaal L. Long term magnesium supplementation influences favourably the natural evolution of neuropathy in Mg-depleted type 1 diabetic patients (T1dm). Magnes Res. 2004;17(2):109-114.